Did you know that 80 percent of generic drugs are manufactured in India or China, thousands of miles from the US FDA inspectors? When it comes to oversight, manufacturing safety, and transparency, it's a huge problem when Big Brother is on the other side of the planet. Generic drugs offer consumers huge cost savings, but is safety and regulation the price we have to pay in order to afford our medicines? On this week's show, you'll meet an investigative journalist who uncovered the real problems with the generic medicine market. Listen & Learn: Why you should be most concerned about medicines you take regularly How carcinogens, toxins, and even bacterial/viral infections are a real risk in manufacturing Why 'surprise visits' are impossible for non-US-based manufacturing facilities Why 'first-to-file' incentives encourage companies to cut corners How the Indian concept of Jugaad might be at odds with safety Links & Resources: Katherine's Site ABOUT OUR GUEST Katherine Eban is an investigative journalist and author. Her articles have won international attention and numerous awards appearing in Fortune, Vanity Fair, The New York Times, Self, The Nation, and The New York Observer. Her work has been featured on 60 Minutes, Nightline, and NPR. She is the author of Dangerous Doses and a new book, Bottle of Lies. Nutritional Tip of the Week: Raw Honey Got Questions? Send me a voicemail here: Ask Lucas a Question Or write to us: [email protected] Like the Show? Leave us a Review on iTunes
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
#2425 - Ethan Hawke
11 Dec 2025
The Joe Rogan Experience
SpaceX Said to Pursue 2026 IPO
10 Dec 2025
Bloomberg Tech
Donβt Call It a Comeback
10 Dec 2025
Motley Fool Money
Japan Claims AGI, Pentagon Adopts Gemini, and MIT Designs New Medicines
10 Dec 2025
The Daily AI Show
Eric Larsen on the emergence and potential of AI in healthcare
10 Dec 2025
McKinsey on Healthcare
What it will take for AI to scale (energy, compute, talent)
10 Dec 2025
Azeem Azhar's Exponential View